Nebenwirkungen · Lucentis
Lucentis 10 mg/ml solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 36–37
HOS-117017 · Präparat HOS-094515
36 Investigations Very common Intraocular pressure increased # Adverse reactions were defined as adverse events (in at least 0.5 percentage points of patients) which occurred at a higher rate (at least 2 percentage points) in patients receiving treatment with Lucentis 0.5 mg than in those receiving control treatment (sham or verteporfin PDT). * observed only in DME population **from post-marketing reporting
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:52:00Z · SHA-256 99f5c71aa34ea0289059cf6afa389329036ec0035d42e5a4cfeaefbb65a1300c · Passage 515c19d0efb2af0404a17001bb6ec489349a50d2940580da34cf8577d208af23 · Zeichen 4260–4699 im Abschnitt